97170-25-7

Upstream product

• 97150-09-9 1-<(1,1-dimethyl-2-propenyl)oxy>hexadecane 
• 97150-11-3 <1-(hexadecyloxy)-1-methylethyl>oxirane 
• 6068-28-6 tosylate de n-hexadecyle 
• 115-18-4 2-methyl-3-buten-2-ol 
• 97150-13-5 3-(hexadecyloxy)-3-methyl-1,2-butanediol 
• 14470-28-1 mono-4-methoxytrityl chloride 

Downstream Products

• 97150-17-9 3-(hexadecyloxy)-3-methyl-2-(phenylmethoxy)-1-butanol 
• 97150-23-7 4-hydroxy-N,N,N,8,8-pentamethyl-7-(phenylmethoxy)-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide, hydroxide 

Relevant academic research and scientific papers

Antihypertensive phosphate derivatives

Antihypertensive phosphate derivatives having the following formula are described: STR1 wherein X is a C1 -C24 branched or straight chain alkyl group; R is selected from the group consisting of hydrogen and C1 -C4 alkyl, with the proviso that at least one R group is not hydrogen; T is selected from the group consisting of hydrogen and STR2 wherein R1 is selected from the group consisting of hydrogen, C1 -C4 branched or straight chain alkyl, C1 -C4 branched or straight chain alkoxy and C1 -C4 branched or straight chain alkylamino; Q is a bivalent radical selected from the group consisting of --(CH2)p -- and --(CHR1)p --, wherein p is an integer from 2 to 12 and the moiety --(CHR1)p -- represents an alkylene chain which is substituted by one or more C1 -C10 alkyl groups or phenyl groups; Z is selected from the group consisting of STR3 wherein R2 may be chain alkyl and q is an integer from 4 to 7; in either the racemic or in the optically active form.

Analogues of Platelet Activating Factor (PAF). 2. Some Modifications of the Glycerine Backbone

Racemic analogues of platelet activating factor (PAF) that contain a methylene group between the C2 and C3 carbon atoms (39) or between the C1 and C2 carbon atoms (40) have been synthesized.These compounds show reduced platelet aggregation and hypotensive activity as measured against racemic C16 PAF.Compounds in which the C1 carbon atom of PAF is substituted with one or two methyl groups (41 and 42, respectively) or the C3 carbon is substituted with a single methyl group (43) have been synthesized.Platelet aggregation and hypotensive responses producedby these compounds are significantly less than those obtained with racemic C16 PAF.None of the above compounds exhibit a separation of the platelet aggregation and hypotensive activities.